A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a rise in circulating LDL cholesterol (LDL‐C). RG7652 is a fully human monoclonal antibody against PCSK9. This placebo‐controlled, phase 1 ascending‐dose study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cardiol
Hlavní autoři: Baruch, Amos, Luca, Diana, Kahn, Robert S., Cowan, Kyra J., Leabman, Maya, Budha, Nageshwar R., Chiu, Cecilia P.C., Wu, Yan, Kirchhofer, Daniel, Peterson, Andrew, Davis Jr, John C., Tingley, Whittemore G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley Periodicals, Inc. 2017
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490403/
https://ncbi.nlm.nih.gov/pubmed/28326559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22687
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky